KRAS and melanoma: We found that 2.5-μM TTM or low 0.1-μM DSF did not suppress growth and metabolic activity in two wt p53 human melanoma cells harbouring KRAS mutation and high c-MYC (C8161) or BRAF mutation and low c-MYC (A375) (Figure 1).